Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03132571 · ClinicalTrials.gov registry record · Phase 2
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03132571 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT03132571, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie reduction diet recommendation for weight and health risk reduction in 40 overweight/obese individuals with schizophrenia.
Interventions
- OTHER Placebo
- DRUG Bupropion
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2018-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03132571
The ClinicalTrials.gov registry entry for NCT03132571 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03132571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03132571 about?
NCT03132571 is a clinical study titled "Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia". The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie reduction diet recommendation for weight and health risk reduction in 40 ...
What is the current status of trial NCT03132571?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-06-01. Estimated completion is 2018-07-31.
What interventions are being tested in trial NCT03132571?
The interventions under investigation include: Placebo (OTHER), Bupropion (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT03132571?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.